Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Current Assets (2016 - 2025)

Historic Current Assets for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $133.4 million.

  • Kyntra Bio's Current Assets fell 4543.67% to $133.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.4 million, marking a year-over-year decrease of 4543.67%. This contributed to the annual value of $196.5 million for FY2024, which is 4073.18% down from last year.
  • As of Q3 2025, Kyntra Bio's Current Assets stood at $133.4 million, which was down 4543.67% from $162.3 million recorded in Q2 2025.
  • Kyntra Bio's Current Assets' 5-year high stood at $621.7 million during Q1 2021, with a 5-year trough of $133.4 million in Q3 2025.
  • Its 5-year average for Current Assets is $376.6 million, with a median of $411.4 million in 2023.
  • Per our database at Business Quant, Kyntra Bio's Current Assets skyrocketed by 395.88% in 2022 and then plummeted by 4908.1% in 2024.
  • Kyntra Bio's Current Assets (Quarter) stood at $474.1 million in 2021, then increased by 3.96% to $492.8 million in 2022, then tumbled by 32.72% to $331.6 million in 2023, then plummeted by 40.73% to $196.5 million in 2024, then plummeted by 32.1% to $133.4 million in 2025.
  • Its Current Assets stands at $133.4 million for Q3 2025, versus $162.3 million for Q2 2025 and $148.5 million for Q1 2025.